In addition, rearrangements or mutations of NF-κB2 leading to sequential non-canonical activation of NF-κB have also been found in various human malignancies, including multiple myeloma, and T-cell and B-cell lymphoma [91,92]. Here, NFKB1 is linked to plasma cell myeloma.